BioSpace News Archive

BiomeFx is an innovative and accurate gut microbiome test launched earlier this year by Microbiome Labs.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has completed enrollment of 30,000 participants for the Phase 3 COVE study of mRNA-1273, its vaccine candidate against COVID-19, being conducted in collaboration with National Institute of Allergy and Infectious Diseases (NIAID)

Report investigates reasons behind inequities, finds impact of COVID-19 on Latinx community likely underestimated

Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its third quarter 2020 operating results on Thursday, November 5, 2020 after market close,

Sharp Fluidics LLC announced the launch of the NeoClose® AnchorGuard following acquisition of NeoClose this past March.

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted, first-in-class medicines to improve the lives of patients with kidney and cardiovascular diseases, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today highlighted new clinical data presented within five posters at Kidney Week 2020,

The COUNTQTM system from VeristaTM is helping pharmaceutical companies accelerate COVID-19 vaccines from development to manufacturing with accelerated technology transfer

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new research from the PROspective sTudy of pEglotiCase in Transplant patients (PROTECT) trial supporting the use of KRYSTEXXA (pegloticase injection) for people who are living with chronic gout refractory to conventional therapies (also known as uncontrolled gout) and have undergone a kidney transplant.

– All Participants Receiving Nedosiran, Regardless of Subtype, Achieved Normalization or Near-Normalization of Urinary Oxalate, a Key PH Measure, by Day 180 in Ongoing, Open-Label Trial – – Nedosiran Was Generally Well Tolerated With No Serious Safety Concerns Identified in This Ongoing Study –

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on November 3rd, 2020 its financial results and operational progress for the third quarter ending September 30th, 2020. GW will also host a conference call the same day at 8:30 a.m. EST. Conference call inf